Written in Blood

Written in Blood

Research from recent issues of Blood

WIB_icon

Number of Older Patients Receiving AlloHCT Increased Over the Past Decade

Historically, older adults have not been considered optimal candidates for hematopoietic cell transplantation (HCT) because of concerns about transplant-related toxicity and mortality. Over the...
WIB_icon

Examining Nilotinib to Prevent Post-Transplant Relapse in Patients With Ph+ Leukemia

In previous research published in Blood, Paul A. Carpenter, MBBS, from the Fred Hutchinson Cancer Research Center in Seattle, Washington, and co-authors determined that...
WIB_icon

For Lenalidomide-Refractory Myeloma, Pomalidomide Is a Safe, Effective Secondline Option

While it has become a standard to include lenalidomide in the frontline treatment of patients with multiple myeloma (MM), most patients have disease that...
WIB_icon

Long-Term Study Confirms Durable Responses With Reduced-Intensity Conditioning AlloHCT in High-Risk CLL

Ten-year follow-up data from the prospective phase II CLL3X trial of the German CLL Study Group confirms that patients with high-risk chronic lymphocytic leukemia...
WIB_icon

Managing GVHD Following HCT: New Uses for Old Treatments?

Graft-versus-host disease (GVHD) remains a major complication following allogeneic hematopoietic cell transplantation (alloHCT) and, when severe, is associated with poor long-term overall survival. Two...

Long-Term Study Confirms Durable Responses With Reduced-Intensity Conditioning AlloHCT in High-Risk CLL

Ten-year follow-up data from the prospective phase II CLL3X trial of the German CLL Study Group confirms that patients with high-risk chronic lymphocytic leukemia...
WIB_icon

Population-Based Study Finds Persistent Gaps in Understanding and Identification of VTE Risk

An estimated 500,000 venous thromboembolism (VTE) events occur annually in the United States, about half of which are related to current or recent hospitalizations,...
WIB_icon

Isatuximab Plus Lenalidomide and Dexamethasone Active in Relapsed/Refractory Multiple Myeloma

Treatment with the investigational anti-CD38 monoclonal antibody isatuximab (in combination with lenalidomide and dexamethasone) led to an overall response rate (ORR) of 51 percent...
WIB_icon

Clonal Hematopoiesis Almost “Inevitable” in Older Adults

Using whole-genome sequencing (WGS) data, Florian Zink, from deCODE genetics/Amgen Inc. in Reykjavik, Iceland, and co-authors found that clonal hematopoiesis (CH) is highly prevalent...
WIB_icon

Rates of Myeloid Neoplasms in Patients With Unexplained Cytopenias

Patients with unexplained cytopenias may never receive a definitive diagnosis, or may eventually be classified as having myelodysplastic syndromes (MDS, a myeloproliferative neoplasm ...
Advertisement

Current Issue

August 2017, Volume 3, Issue 10

This issue features a comparison between American and European drug approval processes, a conversation with a lymphoma doctor running for Congress, highlights from recent hematology/oncology meetings, and more.